<DOC>
	<DOCNO>NCT00295100</DOCNO>
	<brief_summary>The project double blind , randomize , placebo-controlled phase II chemoprevention trial . Study participant randomly assign receive either tamoxifen placebo one year . Participants subsequently follow one year medication . The primary objective evaluate effectiveness tamoxifen reduce breast density mammogram .</brief_summary>
	<brief_title>Tamoxifen-MRI Study</brief_title>
	<detailed_description>The project double blind , randomize , placebo-controlled phase II chemoprevention trial . The study outcomes biological marker , rather cancer incidence mortality . Eligible study subject woman , age 25-45 , whose calculated lifetime breast cancer risk &gt; 20 % ( 25 % Couch model ) . Study participant randomly assign receive either tamoxifen placebo one year . Participants subsequently follow one year medication . The primary objective evaluate effectiveness tamoxifen reduce breast density mammogram . Mammographic density correlate breast cancer risk reduce breast density may add benefit improve sensitivity breast cancer screen young woman . Breast density employ marker progression-related - proliferative - mechanisms carcinogenesis . Secondary study outcome include estrogen ratio ( catechol estrogen/estradiol ) , marker oxidative DNA damage peripheral blood urine ( marker progression-related – mutational - event carcinogenesis ) . The responsiveness outcomes suggest mechanism tamoxifen exerts preventive effect . Persistence marker one year treatment may also provide early information anticipate duration tamoxifen effect .</detailed_description>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Study participant include healthy premenopausal woman , age 25 45 meet follow eligibility criterion : Signed date informed consent document ( 2 ) study accordance applicable Federal , State Institutional regulation Lifetime breast cancer risk &gt; 20 % base Gail model , Claus model , know familial breast cancer susceptibility mutation , predict probability BRCA1/2 mutation &gt; 25 % Couch model diagnosis LCIS DCIS , &gt; 20 Gy external beam radiation deliver chest wall . Regular monthly menstrual period premenopausal define cycle occur every 21 – 35 day Negative serum pregnancy test Prior tubal ligation willingness use nonhormonal barrier method contraception two ( 2 ) year Prior randomization , baseline radiology test result ( mammogram , MRI biopsy , applicable ) must review confirm absence invasive cancer . Study participant exclude follow condition occur : Absence irregular menstrual period . Irregular menstrual period define menstrual cycle occur &lt; 21 day &gt; 35 day within last six month serum LH &gt; 45 . Oral contraceptive hormonal treatment within 3 month study entry . The participant consider deferred 3 month agrees discontinue use oral contraceptive pill hormonal treatment . History evidence malignancy Use follow concurrent medication : Anticoagulant therapy ( e.g . coumarin contain agent lovanox ) , estrogen ( include Estring ) , progestins , androgen , ovarian steroid hormone . Concurrent serious medical illness include : Uncontrolled Diabetes Mellitus ( define HgA1C &gt; 9.0 % ) Uncontrolled hypertension ( define systolic &gt; 180 diastolic &gt; 110 average 2 reading take 2 visit initial visit . ) Thromboembolic disease ( DVT PE ) Cerebrovascular disease ( CVA TIA ) Liver disease ( AST and/or ALT &gt; 2 X normal ) Renal disease ( BUN &gt; 30 mg/dl Creatinine. &gt; 2.0 mg/dl ) Pregnant breast feed Breast implant Prophylactic mastectomy Bilateral oophorectomy ( TAH without BSO permit ) Greater 3 month prior participation chemoprevention trial participation chemoprevention trial within last 6 month Prior treatment tamoxifen &gt; 3 month duration time past Prior treatment Raloxifene &gt; 3 month duration time past Contraindications MRI : presence implant metal include pacemaker , ferromagnetic aneurysm clip , ferromagnetic implant Refusal undergo MRI Deferral Criteria : Study participant defer study time period state following condition occur . If participant treat tamoxifen le 3 month , within last 6 month , defer six ( 6 ) month date last dose . If participant treat Raloxifene le 3 month , within last 6 month , defer six ( 6 ) month date last dose . If participant pregnant breast feeding defer six ( 6 ) month end pregnancy breastfeeding . At time , eligibility status reevaluate . The participant consider deferred three ( 3 ) month agree discontinue use oral contraceptive pill , use “ emergency contraceptive pill ” ( ECP morning pill ) hormonal treatment . If participant open breast biopsy within last two month clinical indication open breast biopsy , pathology result must review . If PATHOLOGY NEGATIVE invasive cancer , defer two ( 2 ) month date last biopsy .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Tamoxifen</keyword>
	<keyword>Prevention</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>MRI</keyword>
</DOC>